April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Advanced Glycation Endproducts (AGEs) Modulate Microglial Activation and Link to Proinflammatory Pathology During Diabetic Retinopathy
Author Affiliations & Notes
  • M. S. Ward
    Opthamology, Centre for Vision and Vascular Science, Belfast, United Kingdom
  • H. Zong
    Opthamology, Centre for Vision and Vascular Science, Belfast, United Kingdom
  • R. Hamilton
    Opthamology, Centre for Vision and Vascular Science, Belfast, United Kingdom
  • A. Madden
    Opthamology, Centre for Vision and Vascular Science, Belfast, United Kingdom
  • A. W. Stitt
    Opthamology, Centre for Vision and Vascular Science, Belfast, United Kingdom
  • Footnotes
    Commercial Relationships  M.S. Ward, None; H. Zong, None; R. Hamilton, None; A. Madden, None; A.W. Stitt, None.
  • Footnotes
    Support  Department of Eduction and Learning
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5646. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. S. Ward, H. Zong, R. Hamilton, A. Madden, A. W. Stitt; Advanced Glycation Endproducts (AGEs) Modulate Microglial Activation and Link to Proinflammatory Pathology During Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5646.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : There is a growing recognition that diabetic retinopathy (DR) is associated with inflammatory pathology. This may be linked to increased numbers and activation of microglial cells in the diabetic retina. Since retinal accumulation of AGEs is a well-defined pathway in DR pathogenesis the current study has sought to determine if these adducts could modulate microglia in vitro and in vivo.

Methods: : Streptozotocin-induced diabetes was initiated in two groups of Sprague Dawley rats and one of the groups was treated with the AGE inhibitor pyridoxamine (PM) (1 g/ml in drinking water). Age-matched, non-diabetic rats were used as controls. Following 3 months diabetes, retinal flat-mounts were evaluated for microglial numbers and activation state using CD11b. Retinal cryosections were also immunolabelled for microglia and imaged by confocal microscopy. Parallel in vitro studies were carried out using BV-2 and EOC-20 microglial cell lines treated with AGE-modified proteins. MAPK signalling pathway activation, inducible nitric oxide synthase (iNOS) expression, nitric oxide (NO) release and pro-inflammatory cytokine mRNA expression were assessed.

Results: : In comparison to non-diabetic controls, an increased number of microglia occurred in the diabetic retina and these cells also showed a change from dendritic (resting) to amoeboid (activated) morphology (P<0.01). PM treatment prevented this response. Exposure of microglia cells to AGEs including AGE-albumin and CML-albumin in vitro induced the activation of p44/42 MAPK signalling pathway, enhanced nuclear translocation of NF-ΚB p65 subunit and overexpression of iNOS as measured by Western blot. The Griess assay showed an increased release of NO into cultured medium in AGEs-treated microglia cell lines (P<0.01). Realtime RT-PCR revealed that iNOS and the pro-inflammatory cytokines TNF-α, IL6 and CXCL1, were significantly increased in AGE-exposed microglia when compared to controls (p<0.05).

Conclusions: : AGE accumulation in the diabetic retina is linked to enhanced numbers and activation of microglia. These adducts can trigger MAPK signal transduction leading to downstream pro-inflammatory responses associated with DR.

Keywords: microglia • inflammation • diabetic retinopathy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×